Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
Status:
Completed
Trial end date:
2013-11-26
Target enrollment:
Participant gender:
Summary
This phase II trial is studying the side effects and how well ixabepilone works in treating
patients with persistent or recurrent uterine cancer. Drugs used in chemotherapy, such as
ixabepilone, work in different ways to stop the growth of tumor cells, either by killing the
cells of by stopping them from dividing.